Meningitis B Outbreak in Kent: Vaccine Demand Surges

CANTERBURY, England – Young people in south-east England are seeking the meningitis B vaccine following an outbreak in Kent that has resulted in two deaths, leading to supply concerns from pharmacies and prompting a review of public health responses to the disease.

Outbreak Details and Public Health Response

Individuals concerned about potential exposure in the Kent outbreak can access the meningitis B vaccine and preventative antibiotics through the UK Health Security Agency (UKHSA), available at university buildings, clinics, and through their general practitioners.

As of March 20, 2026, 18 laboratory-confirmed cases of invasive meningococcal disease have been identified in Kent, with 11 additional notifications under investigation, bringing the total to 29. UKHSA confirmed that sadly, two people have died as a result of the outbreak.

The identified strain is a group B meningococcus, sequence type 485 belonging to the larger clonal complex ST-41/44. Initial genetic analysis indicates that the Bexsero vaccine, currently offered in Kent, should provide protection against this strain.

To date, 2,360 vaccinations have been administered, and over 9,000 doses of antibiotics have been distributed as part of the outbreak response.

Increased Demand and Vaccine Shortages

The outbreak has triggered a surge in private demand for the MenB vaccine from individuals worried about the disease beyond the immediate outbreak area. Pharmacies across Britain have reported being “inundated with requests.”

The University of Kent’s vaccination centre experienced long queues, with students waiting up to eight hours to receive the vaccine. Pharmacy chains Boots and Superdrug have warned of shortages and implemented online waiting lists.

The government released 20,000 doses of the meningitis B vaccine from NHS supplies to alleviate shortages in the private market, but the National Pharmacy Association (NPA) suggests this may not fully meet the increased demand.

Understanding Meningococcal Disease and Vaccination

Meningococcal disease is a serious, though uncommon, illness caused by meningococcal bacteria. It can lead to meningitis (inflammation of the brain’s lining) and sepsis (blood poisoning). Symptoms include fever, drowsiness, and vomiting, and the condition can rapidly become severe.

Transmission of MenB requires close and prolonged contact, such as living in the same household or through intimate contact like kissing or sharing items.

Currently, the MenB vaccine (Bexsero, manufactured by GSK, and Trumenba, by Pfizer) is available on the NHS for infants, who are at the highest risk. Privately, the vaccine costs around £200 (approximately $342).

Review of Vaccination Policy

The outbreak has prompted calls for a broader review of the meningitis B vaccination schedule, particularly regarding adolescents, who are considered the second-highest-risk group. Health Secretary Wes Streeting has requested the Joint Committee on Vaccination and Immunisation (JCVI) to re-examine eligibility criteria for the MenB vaccine on the NHS.

While acknowledging public concern, experts emphasize that antibiotics are the most effective immediate response for those potentially exposed, as they act quickly, while the vaccine requires a month to build immunity.

JCVI decisions are based on cost-benefit analyses, and a single outbreak is unlikely to change their position unless it represents the start of a broader pattern.